Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

January 27th 2024

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

January 27th 2024

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

January 27th 2024

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

January 27th 2024

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

January 27th 2024

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

January 27th 2024

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC

January 27th 2024

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

January 25th 2024

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies

January 24th 2024

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.

Dr Garmezy on Considerations For Frontline Treatment Selection in ccRCC

January 19th 2024

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Dr Bupathi on Updates in the Second-Line Management of Advanced RCC

January 17th 2024

Manojkumar Bupathi, MD, MS, discusses updates in the second-line management of metastatic renal cell carcinoma and anticipated research in this space.

Grivas Expands on Therapeutic Developments and Future Research Directions in GU Cancers

January 17th 2024

Petros Grivas, MD, PhD, discusses the role of PARP inhibitor regimens in prostate cancer, the importance of genetic testing in this setting, and more.

Dr Gruenwald on Tumor Responses With Lenvatinib Plus Pembrolizumab in Advanced RCC

January 16th 2024

Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.

Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCC

January 15th 2024

Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Rate of End-of-Life Immunotherapy Is on the Rise in Advanced Melanoma, NSCLC, RCC

January 15th 2024

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Dr Giles on the Importance of Shared Decision Making When Managing GU Cancers

January 9th 2024

Rachel Giles, MD, PhD, discusses the importance of incorporating shared decision making in the treatment of patients with genitourinary cancers.

Combination Regimens Stir Excitement in Advanced RCC

January 9th 2024

Expert oncologists who treat patients with advanced renal cell carcinoma discuss updates from clinical trials presented during the 2023 ESMO Congress.

Dr Jonasch on the Importance of Spotlighting Patient Advocacy in GU Malignancies

January 8th 2024

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

January 4th 2024

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.